Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) received marketing approval for Sacubitril Valsartan Sodium from China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.
The drug is used to reduce the risk of cardiovascular death and heart failure-related hospitalization in adult patients with chronic heart failure.